255 results about "Pyrazolylchalcone" patented technology

The present invention relates to pyrazolylmethylamine-piperazine derivatives and their pharmaceutically acceptable salts effective as calcium channel modulators and a method of manufacturing the same. The present invention also relates to the medicinal use of the above compounds as therapeutic treatment of diseases due to their effect as calcium channel modulators.

The invention discloses a porous metal-organic framework material, a preparation method and an adsorption and separation application of the porous metal-organic framework material, and belongs to thetechnical field of crystalline materials. The chemical formula is [M (BDP)], wherein M is Zn or Co and the organic ligand is 1, 4-bis (lH-pyrazol-4-yl) benzene (H2BDP). Under the sealing condition, the organic ligand H2BDP, isophthalic acid and cobalt nitrate hexahydrate or zinc nitrate hexahydrate are subjected to thermal reaction in a mixed solution of N, N-dimethylformamide, ethanol and water to obtain crystals of the metal-organic framework. In the structure of the metal-organic framework, benzene rings of the ligand have 'face-to-face' pi-pi action, and the ligand is arched. The materialhas a large specific surface area and a permanent pore structure, and can be used as a material for separating ethane-ethylene mixed gas from propane-propylene mixed gas.

The present application relates to: (a) compounds of Formula (I):

and salts thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, m, n, X and Y are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use for the treatment and prevention of diseases such as those associated with oxidative stress and inflammation.

The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The present invention further provides pharmaceutical compositions comprising the compounds of this invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the compounds of this invention in vivo.

The invention discloses a tri pyrazole ligand based nickel metal organic framework material, and a preparation method and applications thereof, and belongs to the technical field of crystalline statematerial. The chemical molecular formula is [Ni8(OH)4(OH2)2(BTPP)4], H3BTPP is used for presenting organic ligand 4, 4'-(5'-(4-(1H-pyrazole-4-yl)phenyl)-[1, 1':3'-1''-tetraphenyl]4, 4''-di yl)bi(1H-pyrazole). The tri pyrazole ligand based nickel metal organic framework material is synthesized under sealing conditions, organic ligand tri pyrazole ligand based nickel metal organic framework material(H3BTPP) and nickel nitrate are subjected to solvothermal reaction in a mixed solution of N, N-dimethyl formamide and water so as to obtain the tri pyrazole ligand based nickel metal organic framework material. The tri pyrazole ligand based nickel metal organic framework material is low in absorption capacity on low carbon hydrocarbons.

This charge-transporting varnish, which contains a solvent, an electron-accepting dopant substance, and an aryldiamine compound represented by formula (1), imparts a charge-transporting thin film that has high transparency and can evince favorable element characteristics when applied to an organic EL element.

(In the formula: R¹-R⁴ each independently represent a hydrogen atom, a halogen atom, a nitro group, a cyano group, a hydroxyl group, a thiol group, a phosphate group, a sulfone group, a carboxyl group, an alkoxy group having 1-20 carbon atoms, or the like; R⁵-R⁸ each independently represent a hydrogen atom, a phenyl group, a naphthyl group, a pyridyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazinyl group, a furanyl group, a pyrrolyl group, a pyrazolyl group, an imidazolyl group, a thienyl group, or the like; and n represents an integer from 2 to 5.)

The invention discloses a metal-organic framework based on a tripyrazole ligand, a preparation method and application of the metal-organic framework in organic dye degradation, and belongs to the technical field of crystalline materials. The chemical formula of the metal-organic framework is [Zn7 (OH) 2 (TPA) 4 (H2O)], and the organic ligand is 4, 4 ', 4'-tri (1H-pyrazole-4-yl) triphenylamine (H3TPA). The preparation method comprises the following steps: under a sealed condition, carrying out thermal reaction on an organic ligand H3TPA, zinc nitrate hexahydrate and 4, 4 '-dipyridyl in a mixed solution of N, N-dimethylformamide and water to obtain a crystal of the metal-organic framework. The metal-organic framework material has a relatively large specific surface area and a permanent porous structure, and the integrity of the framework structure can be kept in an aqueous solution environment with the pH value of 2-13. The material has visible light absorption performance and can be used as a catalyst for photocatalytic degradation of organic dye in a water body.

Provided is a compound capable of effectively control worst weeds of higher leaf stages that present practical problems. A specific pyrazolylpyrazole derivative of formula (1) is disclosed that is able to solve the above-mentioned problems.

The invention discloses pyrazolyl steroid derivatives having a structure shown in the formula (I) in the specification, wherein substituent R1 can be H, nitryl or halogen, substituent R2 can be C1-C6 alkyl, hydroxy-substituted C1-C6 alkyl or monosubstituted or polysubstituted aryl. The synthesis route of the pyrazolyl steroid derivatives takes pregnenolone as a raw material; the method is used for synthesizing the pyrazolyl steroid derivatives for the first time and has the advantages of high yield, easy separation and the like. The pyrazolyl steroid derivatives show inhibitory activity for human lung adenocarcinoma cell, cervical carcinoma cell line and hepatoma carcinoma cell and have a prospect of being developed into anti-cancer drug or medicine compositions.

The invention discloses a silicon-nitrogen compound as well as a preparation method and application thereof. The structural formula of the silicon-nitrogen compound is as shown in a formula I, wherein X radical is one radical or a combination of radicals selected from pyrazolyl, substituted pyrazolyl, imidazolyl, substituted imidazolyl or amino. The silicon-nitrogen compound disclosed by the invention has a higher vulcanization rate for RTV (Room Temperature Vulcanization) silicon rubber under the room temperature and can be used for providing better heat resistance to the silicon rubber, better bonding strength to the steel and bigger application value.

The invention provides a novel crystal form of (1S, 4R)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl) pyridine-3-yl) ethyl)-1-methoxy-4-(4-methyl-6-((5-methyl-1H-pyrazol-3-yl) amino) pyrimidine-2-yl) cyclohexane formamide (a compound represented by a formula (I)) and a preparation method thereof.

The invention discloses a preparation method of chlorantraniliprole and an intermediate of chlorantraniliprole, which comprises the following steps: in the presence of an alkali and a solvent, mixing3-bromo-1-(3-chloro-2-pyridyl)-1H-pyrazole-5-carboxylic acid and 2-amino-5-chloro-3-methylbenzoic acid together to form a material I; and mixing the methylsulfonyl chloride with the material I, and carrying out a reaction so as to obtain a 2-[3-bromo-1-(3-chloro-2-pyridyl)-1H-pyrazol-5-yl]-6-chloro-8-methyl-4H-3, 1-benzoxazine-4-one intermediate, i.e., a chlorantraniliprole intermediate. The method is easy to operate, the benzoxazinone intermediate generated in the reaction process does not need to be further treated, can be adopted in a next step of reaction directly without drying for preparation of chlorantraniliprole; the method has the advantages that the method is simple in process and high in total yield and product quality, a filtrate can be used by the aid of synchronous and continuous application processes, accordingly, the usage amount of the solvent can be reduced to a great extent, and the method is suitable for industrial production.

The present invention relates to compounds of Formula I:

wherein A is (CH₂)_m-Q-(CH₂)_n, wherein each CH₂ may be independently substituted with one or more substitution selected from the group consisting of: hydroxy, halo, alkoxy, lower alkyl, amino, aminoalkyl, alkylamino, alkenyl, and alkynyl; B is a 5 or 6 membered heteroaryl, or aryl, optionally saturated, or optionally substituted with R¹, R², or R¹²; X is selected from the group consisting of: N and C; and Y and Z are independently selected from the group consisting of: N, C, CH, CR³, S, and O; compositions comprising such compounds, intermediates thereof, methods of making such compounds, and methods for treating cancer, inflammation, and inflammation-associated disorders, such as arthritis.

The invention provides a polypyrazole nitrogen heterocyclic compound as well as preparation and application thereof. The polypyrazole nitrogen heterocyclic compound is tris((5-(pyrazol-4-yl)pyridin-2-yl)methyl)amine, the chemical formula thereof is C27H24N10, the structural formula is shown in the description, the tris((5-(pyrazol-4-yl)pyridin-2-yl)methyl)amine is an important hydrogen bond acceptor and can be used for constructing an identifier of anions by utilizing the weak interaction of hydrogen bonds of the tris((5-(pyrazol-4-yl)pyridin-2-yl)methyl)amine. The polypyrazole nitrogen heterocyclic compound provided by the invention, which serves as a halide ion identifier, has high sensitivity to fluorine, chlorine, and bromide ions in an aqueous system, and is not interfered by other anions.

The invention discloses a synthesis method of chlorantraniliprole, which comprises the following steps: dissolving phosgene in a solvent to form a material A, mixing 3-bromo-1-(3-chloro-2-pyridyl)-1H-pyrazole-5-carboxylic acid and 2-amino-5-chloro-3-methylbenzoic acid as raw materials in the presence of alkali and the solvent, and adding the material A to carry out a reaction to obtain 2-(3-Bromo-1-(3-chloro-2-pyridyl)-1H-5-pyrazolyl)-6-chloro-8-methyl-4H-benzo[d][1,3]oxazine-4-one (oxazinone, for short), and directly reacting the oxazinone with monomethylamine without purification to synthesize the chlorantraniliprole. The synthesis method has the advantages of cheap raw materials, high reaction activity, simple post-treatment process and no residue; the reaction synthesis conditions aremild, less three wastes are generated, special equipment is not needed, and industrial production is easy to realize.